Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Share-based Compensation: 2010-2025

Historic Share-based Compensation for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $5.7 million.

  • Catalyst Pharmaceuticals' Share-based Compensation rose 28.16% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 13.87%. This contributed to the annual value of $22.3 million for FY2024, which is 56.15% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Share-based Compensation of $5.7 million as of Q3 2025, which was down 25.37% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Share-based Compensation ranged from a high of $8.2 million in Q1 2024 and a low of $1.5 million during Q4 2021.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Share-based Compensation value was $4.4 million (recorded in 2024), while the average stood at $5.1 million.
  • In the last 5 years, Catalyst Pharmaceuticals' Share-based Compensation spiked by 185.20% in 2024 and then fell by 29.07% in 2025.
  • Catalyst Pharmaceuticals' Share-based Compensation (Quarterly) stood at $1.5 million in 2021, then soared by 30.84% to $1.9 million in 2022, then soared by 120.66% to $4.2 million in 2023, then climbed by 21.67% to $5.2 million in 2024, then climbed by 28.16% to $5.7 million in 2025.
  • Its last three reported values are $5.7 million in Q3 2025, $7.6 million for Q2 2025, and $5.8 million during Q1 2025.